000225.KO Yuyu Pharma Inc
- Market cap
- KRW 42.5B
- P/E
- -
- P/B
- -
- ROE
- 10.6%
- Dividend yield
- 4.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 000225.KO undervalued?
Graham numberThe Graham number of Yuyu Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yuyu Pharma Inc fundamental analysis
No fundamental analysis for Yuyu Pharma Inc yet.
Yuyu Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Full company profileYuyu Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yuyu Pharma Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 71.6B | 62.9B | 83.1B | 90.9B | 98.1B | 116B | 139B | 137B | 133B | 141B | 144B |
| Gross Profit | 33.4B | 30.0B | 40.6B | 46.6B | 45.3B | 45.3B | 53.3B | 48.9B | 51.7B | 53.9B | 58.6B |
| Operating Income | 3.73B | 3.57B | 5.33B | 8.07B | 6.27B | 1.20B | -592M | 365M | 12.6B | 11.0B | 16.6B |
| EBITDA | - | 6.66B | 7.90B | 11.5B | 9.37B | 6.30B | 3.80B | 2.72B | 18.9B | 17.6B | 23.7B |
| Net Income | 5.89B | 4.54B | 4.02B | 4.72B | 1.28B | -2.21B | -5.99B | -7.18B | 8.72B | 8.15B | 14.3B |
| EPS | 1,031 | 384 | 343 | 402 | 86 | -133 | -366 | -444 | 539 | 518 | 907 |
| Balance Sheet | |||||||||||
| Total Assets | 111B | 121B | 135B | 138B | 155B | 193B | 195B | 198B | 208B | 207B | 208B |
| Total Liabilities | 33.0B | 38.7B | 48.4B | 47.2B | 37.9B | 64.3B | 71.8B | 77.9B | 72.6B | 66.7B | 61.7B |
| Shareholders' Equity | 77.2B | 82.0B | 85.8B | 88.7B | 114B | 124B | 117B | 112B | 125B | 130B | 135B |
| Cash & Short-term Investments | 18.9B | 19.8B | 27.0B | 26.8B | 20.3B | 50.3B | 25.8B | 30.6B | 41.8B | 29.1B | 21.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.82B | 561M | 6.11B | 13.2B | -2.67B | 4.51B | -6.23B | 421M | 25.0B | 15.9B | 15.7B |
| Capital Expenditure | 2.32B | 5.19B | 9.76B | 8.06B | 12.0B | 6.07B | 5.28B | 5.11B | 7.30B | 8.45B | 17.4B |
| Free Cash Flow | - | -3.20B | -3.96B | 4.45B | -17.0B | -2.24B | -11.8B | -4.69B | 17.6B | 7.42B | -1.68B |
| Ratios | |||||||||||
| ROE | 7.6% | 5.5% | 4.7% | 5.3% | 1.1% | -1.8% | -5.1% | -6.4% | 7.0% | 6.3% | 10.6% |
| ROA | 5.3% | 3.7% | 3.0% | 3.4% | 0.8% | -1.1% | -3.1% | -3.6% | 4.2% | 3.9% | 6.9% |
| Net Profit Margin | 8.2% | 7.2% | 4.8% | 5.2% | 1.3% | -1.9% | -4.3% | -5.2% | 6.5% | 5.8% | 9.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Yuyu Pharma Inc dividends
- Dividend yield
- 4.53%
- Forward dividend
- 125.00 KRW
- Payout ratio
- 23.7%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.93B | 122 | 23.7% |
| 2024 | - | - | - |
| 2023 | KRW 2.00B | 124 | - |
| 2022 | KRW 2.03B | 124 | - |
| 2021 | KRW 1.85B | 111 | - |
| 2020 | KRW 1.52B | 102 | 118.4% |
| 2019 | KRW 1.44B | 123 | 30.6% |
| 2018 | KRW 1.38B | 118 | 34.4% |
| 2017 | KRW 1.27B | 108 | 28.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 30, 2021.
Who owns Yuyu Pharma Inc
- Insiders 8.48%
- Institutions 0.00%
- Public & others 91.52%
- Shares outstanding 5.86M
- Free float 10.1M
Yuyu Pharma Inc company profile
- Company name
- Yuyu Pharma Inc
- Ticker
- 000225.KO
- ISIN
- KR7000221002
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 243
- Fiscal year end
- December
- Address
- 94 Biovalley 1-ro, Jecheon-si, South Korea, 27159
- Phone
- 82 4 3652 7981
- Website
- yuyu.co.kr
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Yuyu Pharma Inc management
2- Mr. Wonsang YuCEO & Director · born 1974
- NoYong ParkCEO & Inside Director